Expiration date: 12/2026

Composition

Active ingredient: dexpanthenol 50 mg

Excipients: cetrimide — 0.1 mg; disodium edetate — 0.1 mg; carbomer — 0.1 mg; sodium hydroxide — 1.01 mg; water for injection — 945.79 mg

Dosage form

Dexpanthenol

Description

The gel

Pharmacodynamics

Transparent or slightly opalescent, colorless, easily flowing gel.

Pharmacokinetics

The active ingredient of the Korneregel preparation is dexpanthenol/panthenol, a precursor of pantothenic acid, which thus has all the same biological properties as D-pantothenic acid, which, having been converted into coenzyme A in the human body, participates in many metabolic processes. The data obtained in animal experiments indicate an increase in fibroblast proliferation and the presence of a regenerating effect. When applied externally, dexpanthenol is able to fill the increased need for pantothenic acid in damaged skin or mucous membrane. The eye gel has a high viscosity, which makes it possible to achieve long-term contact of dexpanthenol with the surface of the mucous membrane of the eye.

Indications for use

According to the results of the study of tritium-labeled dexpanthenol, its penetration (adsorption) through the skin has been established.

To increase the duration of contact of an aqueous solution of dexpanthenol with the corneal epithelium, Korneregel contains a carbomer, which, due to its high molecular weight, does not penetrate into the tissues of the eyeball and is not absorbed into the systemic circulation.

Contraindications

• Treatment of keratopathy of a non-inflammatory nature, for example, such as: corneal dystrophy, recurrent erosion, corneal lesions when wearing contact lenses,
• as an adjunct therapy to stimulate the healing process of the cornea and conjunctiva in case of their injuries and burns (chemical and thermal),
• an auxiliary agent in the treatment of infectious corneal lesions of bacterial, viral or fungal origin.

Use during pregnancy and lactation

Individual hypersensitivity to any of the components of the drug.

Side effects

There are no data on the effects of pantothenic acid when ingested on the course of pregnancy and fetal development or the health of the newborn. However, it is known that when ingested, pantothenic acid, into which dexpanthenol is metabolized, freely penetrates through the placenta and is excreted through breast milk in proportion to the amount of the drug taken.

Since there is no data on the concentration of dexpanthenol (pantothenic acid) in blood plasma after topical application in the form of an eye gel, the use of Korneregel during pregnancy and / or breastfeeding is possible only after consultation with a doctor, when the expected benefit to the mother exceeds the potential risk to the fetus and / or child.

Interaction

Itching, hyperemia, conjunctival edema, pain, foreign body sensation, increased lacrimation, transient blurred vision.

Allergic reactions: very rarely - hypersensitivity (itching, skin rashes.

Method of administration and dosage

Cases of incompatibility with other drugs are unknown.

In cases where additional local therapy with eye drops / ointments is performed, the interval between administration of Korneregel and other ophthalmic drugs should be at least 15 minutes.

Due to its physical properties, the drug Korneregel can prolong the residence time of other ophthalmic drugs in the eye and thereby enhance their effect. Therefore, the Root gel should be used last.

Overdose

• Treatment of keratopathy of a non-inflammatory nature, for example, such as: corneal dystrophy, recurrent erosion, corneal lesions when wearing contact lenses,
• as an adjunct therapy to stimulate the healing process of the cornea and conjunctiva in case of their injuries and burns (chemical and thermal),
• an auxiliary agent in the treatment of infectious corneal lesions of bacterial, viral or fungal origin.

Special instructions

After instillation of the drug, a thin film forms on the cornea, which can cause short-term blurred vision, thereby reducing the reaction rate. Therefore, driving vehicles and mechanisms should be started when visual clarity is restored.

Influence on the ability to drive motor vehicles and manage mechanisms

Locally.

In the lower conjunctival sac of the affected eye, 1 drop 4 times a day, as well as 1 drop before bedtime.

Form of release

Korneregel should not be used as monotherapy for infectious corneal lesions of bacterial, viral or fungal origin.

The preservative cetrimide, which is part of the drug, can cause local eye irritation, allergic reactions (burning, redness, foreign body sensation in the eye) and damage to the corneal epithelium if used for a long time or too often.

During treatment with Korneregel, it is not recommended to wear contact lenses due to the possible incompatibility of the drug with the lens material. However, if contact lenses are still shown, they should be removed and put back on no earlier than 15 minutes after instillation of the drug before using the Korneregel preparation.

Do not touch the tip of the pipette tube to the eye.

The tube must be closed after each use.

If there is no improvement in the condition, signs of eye irritation appear, you should stop using the drug and consult a doctor.

Conditions of release from pharmacies

5 g or 10 g each in tubes with a nozzle head and a screw cap made of PVC.

1 tube together with the instructions for medical use in a cardboard box.

Storage conditions

Without a prescription

Expiration date

In a place protected from light, at a temperature not exceeding 25 C. Keep out of reach of children.